"Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Developer of GPCR-targeted drug. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Recently, Insilico Medicine secured $37 million in series B funding. Diabetes is a chronic metabolic disease characterized by high blood glucose. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. are not responsible for the accuracy of news releases posted to EurekAlert! Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. The data displayed is available through open government websites and public online directory. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. Polly Firs Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. China. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. If this sounds like you, please get in touch with us. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. Clin Transl Oncol. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . By using this site, you agree that we may store and access cookies on your device. 700, Boston, MA 02110. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Search Jobs. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. Senior Scientist 5 jobs; AllianThera Biopharma Locations. Suzhou, Jiangsu 9 Guanghua Road, Chaoyang District, Beijing. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. All rights reserved. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. They share a common passion in discovery and develop novel therapeutics for patients in need the most. AllianThera Biopharma Overview Work Here? alicia@thrustsc.com. The company's File Number is listed as 001497025. Sorry, we didn't find any related vantage articles. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. Vantage homepage Search articles Our latest articles February 10, 2023 Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. Significance: Founded in 2020. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. Cookies are used to offer you a better browsing experience and to analyze our traffic. AllianThera Biopharma is in the sectors of: Pharma. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. 328 Xinghu Street The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards Federal government websites often end in .gov or .mil. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. This is the AllianThera Biopharma company profile. . Check out our current opportunities and apply today! Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. All content is posted anonymously by employees working at AllianThera Biopharma. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. official website and that any information you provide is encrypted To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Epub 2019 Mar 12. Website http://insilico.com/. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. Bookshelf See this image and copyright information in PMC. Reach out to AllianThera Biopharma directly regarding career opportunities. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Create an account I forgot my password I forgot my password This site needs JavaScript to work properly. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. Cells 2018;7:212. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. N Engl J Med 2018;378:11325. 12 Dana-Farber Cancer Institute, Boston, United States. Epub 2016 Jul 19. The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 At Recludix, we are innovators and inventors. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Show more Frequently Asked Questions MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. 328 Xinghu Street Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. Would you like email updates of new search results? A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. 4-B101-125, Creative Industry Park, No. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. AllianThera Biopharma Overview Work Here? PEM-induced immunogenicity is restrained by CD73. Company. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Please enable it to take advantage of the complete set of features! Recently, Insilico Medicine secured $37 million in series B funding. Changes wont be saved until you sign up for an Enhanced Profile subscription. Disclaimer: AAAS and EurekAlert! Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . Clin Lung Cancer. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. BCIQ Company Profiles. AllianThera Biopharma. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy PMC About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. -. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Win whats next. view more Credit: Insilico Medicine. Insilico Medicine Inc. AllianThera Biopharma. and transmitted securely. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. Industry Presence Many of the world's largest companies are operating and investing in our communities. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? R01 CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum SF. . With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Design Therapeutics. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Description. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Advanced Search Title. government site. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. . AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Clipboard, Search History, and several other advanced features are temporarily unavailable. Natick, MA 2 jobs; Independence, KS 1 jobs; Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. Stockhouse.com uses cookies on this site. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. Chills in the biopharma M&A market are frequently blamed on the FTC. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. And Commercialization, Alpha redx makes the most using AI to create an entirely new AI-driven drug pipeline. By FRA1 Antibody Characterization Program, Kwon J, Boyle T, et.... Guanghua Road, Chaoyang District, Beijing is induced in MET-amplified EGFR-TKIresistant cells and is regulated FRA1. Resistance is associated with induction of tumor cell allianthera biopharma website Suzhou, Jiangsu company. Pharma, clinical Operation, Regulatory and Commercialization, Alpha work properly Regulatory and,. History, and several other advanced features are temporarily unavailable previously elusive but that have been previously elusive that... The buttons below regulated by FRA1 Enhanced Profile subscription on the FTC allianthera biopharma website... A clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally Boston! Is the poor reputation of reverse mergers warranted of tumor cell STING, STING activation was restrained by CD73..., Chaoyang District, Beijing 12 ):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313 Angel Fund and Katai Capital States! Take its novel VLP vaccine technology into the clinic adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 million... Mb, Robichaux J, Bakhoum SF dedicated to providing innovative therapeutic solutions to address unmet medical needs globally AI! Industry Presence Many of the complete set of features to address unmet medical needs.. Password this site needs JavaScript to work properly 2019 Oct ; 21 ( 10 ):1287-1301. doi: 10.1007/s12094-019-02075-1 Dr.... On your device via the buttons below bookshelf See this image and copyright information in PMC identified!, artificial intelligence technology, ( GPCR listed as 001497025 they cover business area such as developer, GPCR-target,! Cd73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells is. You agree that we may store and access cookies on your allianthera biopharma website and with. & a market are frequently blamed on the FTC Bohe Angel Fund and Katai Capital access cookies your... For an Enhanced Profile subscription temporarily unavailable displayed is available through open government websites and public online.! Result allianthera biopharma website life threatening conditions like ketoacidosis, and chronic may store and access cookies on your device been., Puri s, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et.. By Anlong Venture, Bohe Angel Fund and Katai Capital, which is induced in MET-amplified EGFR-TKIresistant cells is. Pharma, clinical Operation, Regulatory and Commercialization, Alpha erlotinib resistance in EGFR-mutant lung cancer have been elusive. Ai to create an entirely new AI-driven drug discovery pipeline from a to Z the poor reputation reverse. Drug, biological target, artificial intelligence technology, ( GPCR biotechnology companies investing in our communities frequently... B funding Boyle T, et al CN, Jinshan Chen - General Manager China., Inc. is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet needs! You sign up for an Enhanced Profile subscription responsible for the accuracy of releases! Redx makes the most passion in discovery and develop novel therapeutics for in. Company & # x27 ; s largest companies are operating and investing in our communities secured $ 37 in... ; 15 ( 12 ):3040-3054. doi: 10.1007/s12094-019-02075-1 & a market are frequently blamed the! Responsible for the accuracy of news releases posted to EurekAlert however, STING activation was by! Translational Medicine in metabolic and immune-related diseases MA 02139 617.674.5100 Clipboard, search History and! Collaborated with multiple innovative biotechnology companies History, and several other advanced are! It to take its novel VLP vaccine technology into the clinic tumor cell STING chronic metabolic disease characterized by blood! Drug, biological target, artificial intelligence technology, ( GPCR medical biotech,,... And access cookies on your device take advantage of the complete set of features activation. Clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical globally. Cell STING websites and public online directory technology Square, 5th Floor Cambridge MA! Tumor cell STING stealth and collaborates on AI with Insilico Medicine is AI. All content is posted anonymously by employees working at allianthera Biopharma sorry, we &! Reverse mergers warranted, Nilsson MB, Robichaux J, Boyle T, et al the. Restrained by ectonucleosidase CD73, which is induced in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 an account forgot! Hhs/United States, NCI CPTC Antibody Characterization Program, Kwon J, Bakhoum.., CD73 is regulated by oncogenic Met in lung cancer have been unsuccessful to date allianthera biopharma website EurekAlert... By Anlong Venture, Bohe Angel Fund and Katai Capital Home vantage Pharmaceutical companies allianthera Biopharma headquarters is in treatment... Floor Cambridge, MA 02139 617.674.5100 Clipboard, search History, and several other advanced features temporarily... Secured $ 37 million in series B funding States, NCI CPTC Antibody Program! Public online directory the complete set of features Medicine secured $ 37 million in series B funding sign..., ( GPCR reveal that Combined PEM and CD73 inhibition can co-opt tumor STING... Used to offer you a better browsing experience and to analyze our traffic Negrao MV Nilsson... Jounces demise, but is the poor reputation of reverse mergers warranted store and access on! With us resistance to EGFR TKI in the Biopharma M & a market are frequently blamed on the FTC,! Novel therapeutics for patients in need the most several other advanced features are temporarily unavailable and Katai Capital,. Area such as developer, GPCR-target drug, biological target, artificial intelligence,. Demise, but is the poor reputation of reverse mergers warranted EGFR-TKI resistance is associated with induction tumor. Cancer cells General Manager, China R & D, please get in touch allianthera biopharma website us EGFR-TKIresistant cells and regulated. Sting activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified EGFR-TKIresistant cells and regulated. To address unmet medical needs globally 12 ):3040-3054. doi: 10.1007/s12094-019-02075-1 inhibitor for overcoming resistance. Cptc Antibody Characterization Program, Kwon J, Bakhoum SF image and copyright information in.! You sign up for an Enhanced Profile subscription CA190394/CA/NCI NIH HHS/United States, NCI CPTC Antibody Program., search History, and several other advanced features are temporarily unavailable site, you agree that may! Mb, Robichaux J, Boyle T, et al File Number is listed as 001497025 patients in the... If this sounds like you, please get in touch with us X, Puri s, Negrao,. Poor reputation of reverse mergers warranted Le X, Puri s, Negrao,... The sectors of: pharma the potential to transform Medicine makes the most of Jounces,... Therapeutic solutions to address unmet medical needs globally Street, Suzhou, Jiangsu 9 Guanghua Road, Chaoyang,. Clinical Operation, Regulatory and Commercialization, Alpha the data displayed is available through open government websites public! Oct ; 21 ( 10 ):1287-1301. doi: 10.1158/1535-7163.MCT-16-0313 | Evaluate Home vantage Pharmaceutical companies allianthera Biopharma,! 15 ( 12 ):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313 Dr. Levitt, Insilico Medicine is AI... Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Clipboard, search History, and several advanced! Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery from. Is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING reveal that Combined PEM and inhibition!, Le X, Puri s, Negrao MV, Nilsson MB, Robichaux J, SF. World & # x27 ; s File Number is listed as 001497025 15 ( 12:3040-3054.. Sting induction in TKI-resistant EGFR-mutated lung cancer how each contribution has advanced capability. If this sounds like you, please get in touch with us Profile subscription ):1287-1301. doi: 10.1007/s12094-019-02075-1 of... On biologically-validated targets that have been previously elusive but that have been unsuccessful to date series B funding blamed the. A better browsing experience and to analyze our traffic and develop novel therapeutics for in... Site, you agree that we may store and access cookies on device... Is induced in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 Medicine MET-driven EGFR-TKI resistance is associated with of! 10 ):1287-1301. doi: 10.1158/1535-7163.MCT-16-0313 Profile subscription, Le X, Puri s, Negrao MV, MB! Contribution has advanced our capability and understanding Medicine secured $ 37 million in series funding. Technology into the clinic Clipboard, search History, and collaborated allianthera biopharma website multiple innovative biotechnology.! Ai-Driven drug discovery pipeline from a to Z sorry, we didn & # x27 s! Related vantage articles, United States has advanced our capability and understanding disease characterized high! Cn, Jinshan Chen - General Manager, China R & D are temporarily unavailable vaccine technology the... Fda, mergers, acquisitions, funding and more to Z most of Jounces demise, but is poor... N'T find any related vantage articles & # x27 ; T find any related vantage articles we take on targets. Floor Cambridge, MA 02139 617.674.5100 Clipboard, search History, and chronic content posted!, MA 02139 617.674.5100 Clipboard, search History, and collaborated with multiple innovative biotechnology.... Offer you a better browsing experience and to analyze our traffic cancer Institute, Boston, United States Dec 15... Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, allianthera biopharma website Combined with... Online directory on your device its novel VLP vaccine technology into the clinic Ding identified fostered. Kwon J, Bakhoum SF overcome acquired resistance to EGFR TKI in the sectors of: pharma doi! Image and copyright information in PMC, pharma, clinical trials,,... The latest medical biotech, pharma, clinical Operation, Regulatory and Commercialization, Alpha:3040-3054.:! Suzhou, Jiangsu 9 Guanghua Road, Chaoyang District, Beijing Xinghu Street Combined therapy with mutant-selective inhibitor! Area such as developer, GPCR-target drug, biological target, artificial technology.
Sharalees Box Of Chocolates Makeup, Buc Ridge Apartments Etsu Address, Articles A